Core Viewpoint - Kolon Biotech Inc. (06990) shares rose nearly 5% in early trading, reflecting positive market sentiment following the announcement of successful Phase III clinical trial data for SKB264 (sac-TMT) [1] Group 1: Clinical Trial Results - The recent Phase III clinical trial results for sac-TMT indicate a significant advancement, marking the first successful Phase III trial for sac-TMT in first-line treatment of non-small cell lung cancer (NSCLC) [1] - This trial is also noted as the first globally to demonstrate that the ADC+PD-1 combination therapy is superior to PD-1 monotherapy in first-line NSCLC treatment [1] Group 2: Financial Projections and Analyst Ratings - Following the positive trial results, the company plans to submit a supplemental new drug application (sNDA) for sac-TMT targeting relevant indications in China [1] - JPMorgan has raised its revenue forecasts for the company by 1% to 10% for the years 2025 to 2033, and increased the target price from 499 HKD to 545 HKD [1] - The firm continues to view the company positively, maintaining its "overweight" rating and identifying it as a preferred stock in the Chinese biopharmaceutical sector, anticipating multiple catalysts in 2026 [1]
科伦博泰生物-B早盘涨近5% SKB264三期临床试验数据正面 小摩上调收入预测